A head-to-head trial of two widely used TAVR devices in patients with small aortic annuli, mostly women, showed differences in performance at 1 year in the SMART trial.
The benefit in functional outcome is a welcome finding for these deadly strokes but was restricted to a select patient population, one expert suggests.
Ticagrelor monotherapy safely cut bleeding by more than half after intervention for acute coronary syndrome, without an increase in MACCE, in the ULTIMATE-DAPT trial.
Chelation therapy to remove potentially toxic levels of lead was not associated with a reduction in CV events in post-MI patients with diabetes in the TACT2 trial.
ApoA1 infusions in acute MI did not significantly reduce the composite endpoint in the AEGIS-II trial. However, an exploratory analysis suggested benefit at higher LDL levels.